|
 |
|
 |
|
"The 5th Japan
Bio-Venture Award" |
|
| Award by Minister of Education, Culture, Sports, Science and Technology. |
  |
|
|
|
| Oncolys is seeking partnering opportunities for our lead compounds. For more information visit our Partnering opportunities page on this site or contact us at anticancer@oncolys.com |
|
|
|
|
|
|
 |
Oncolys BioPharma is a privately held biopharmaceutical company focused on the development of novel biologics for the treatment of cancer and infectious disease.
We believe that through the development of replication-competent oncolytic virus and micrometastatic tumor diagnostic viruses, we produce safer, more effective, QOL-improving approaches aiming to revolutionize the current mode of cancer therapy.
Our lead compound for the treatment of cancer, Telomelysin® (OBP-301), is in Phase-I clinical development in the US and is being tested in clinical trials for various solid tumors.
Our novel cancer diagnostic compound, Telomescan® (OBP-401), is in a validation stage (feasibility studies) and is expected to effective in detecting most types of cancer.
Our lead compound for infectious disease, FESTINAVIR®(OBP-601), is in Phase-I for HIV/AIDS therapy. OBP-601 is a novel NRTI with highly promising safety and resistance profiles.
|
|
 |
|
|
|
|
|
|
